The FDA accepted a new drug application for SYD-101 to slow the progression of pediatric myopia and assigned a Prescription ...

Myopes may undergo about –1 D of progression between the ages of 20 and 50 years, according to an analysis of three large ...

Every morning – shortly after checking my phone and shortly before brushing my teeth – I pull down my lower eyelids in turn ...

The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for SYD-101 (atropine sulfate) to slow the progression of ...

Regular Eye Checkups Schedule routine eye exams with a pediatrician or ophthalmologist to monitor your child's eye health.

A recent study finds a link between the rise in kids’ worsening vision and screen time. The study, published by Jama Network ...

The FDA has set a PDUFA target action date of October 23, 2025, for the low-dose atropine formulation.

Myopia is a refractive error (blurred vision at a given distance) that affects about 30% of the world's population. This ...

FDA assigns a PDUFA target action date of October 23, 2025 If approved, SYD-101 would be the first and only pharmaceutical treatment option proven to slow the progression of pediatric myopia ...

As technology continues to be an integral part of our daily lives, it’s no surprise that children are spending more time on ...

If approved, SYD-101 would be the first and only pharmaceutical option for the treatment of progression of pediatric myopia in the United States. “The FDA acceptance of our NDA filing for SYD ...